Your browser is no longer supported. Please, upgrade your browser.
Settings
SYBX Synlogic, Inc. daily Stock Chart
SYBX [NASD]
Synlogic, Inc.
Index- P/E- EPS (ttm)-1.68 Insider Own0.40% Shs Outstand34.23M Perf Week-6.02%
Market Cap65.70M Forward P/E- EPS next Y-1.68 Insider Trans0.00% Shs Float26.24M Perf Month-17.37%
Income-54.30M PEG- EPS next Q-0.46 Inst Own50.20% Short Float1.92% Perf Quarter22.64%
Sales2.00M P/S32.85 EPS this Y16.40% Inst Trans-1.19% Short Ratio1.48 Perf Half Y-27.24%
Book/sh4.15 P/B0.47 EPS next Y10.20% ROA-27.90% Target Price- Perf Year-78.33%
Cash/sh3.39 P/C0.57 EPS next 5Y- ROE-33.50% 52W Range1.35 - 9.40 Perf YTD-24.42%
Dividend- P/FCF- EPS past 5Y23.60% ROI-34.60% 52W High-79.26% Beta2.22
Dividend %- Quick Ratio18.70 Sales past 5Y- Gross Margin- 52W Low44.44% ATR0.16
Employees76 Current Ratio18.70 Sales Q/Q-66.70% Oper. Margin- RSI (14)39.58 Volatility5.41% 7.69%
OptionableYes Debt/Eq0.00 EPS Q/Q9.70% Profit Margin- Rel Volume0.82 Prev Close2.00
ShortableYes LT Debt/Eq0.00 EarningsMay 08 BMO Payout- Avg Volume339.04K Price1.95
Recom2.00 SMA20-9.59% SMA50-11.75% SMA200-13.33% Volume277,950 Change-2.50%
Aug-21-19Downgrade Oppenheimer Outperform → Perform
Apr-30-19Initiated Jefferies Buy $18
Dec-13-18Initiated Chardan Capital Markets Buy $20
Mar-19-18Initiated H.C. Wainwright Buy $20
Jan-29-18Initiated Piper Jaffray Overweight $16
Jun-17-20 09:38PM  
Jun-12-20 11:19AM  
Jun-01-20 05:46AM  
May-27-20 08:00AM  
May-21-20 04:02PM  
08:01AM  
06:00AM  
May-08-20 07:44AM  
06:00AM  
May-04-20 04:02PM  
Apr-01-20 07:32AM  
Mar-30-20 06:00AM  
Mar-15-20 11:00AM  
Mar-12-20 04:19PM  
03:00PM  
Mar-11-20 04:02PM  
Mar-05-20 04:02PM  
Feb-19-20 02:04PM  
Feb-18-20 04:02PM  
Jan-24-20 08:01AM  
Jan-14-20 08:33AM  
Jan-09-20 06:00AM  
Jan-06-20 09:20AM  
Dec-20-19 03:29PM  
Dec-12-19 07:55AM  
Dec-11-19 06:00AM  
Dec-10-19 07:00AM  
Dec-05-19 02:37PM  
Nov-25-19 04:02PM  
04:02PM  
Nov-14-19 11:41AM  
Nov-12-19 04:02PM  
Nov-07-19 03:07PM  
Nov-05-19 04:02PM  
Sep-30-19 04:02PM  
Sep-26-19 07:00AM  
Sep-25-19 05:23PM  
Sep-12-19 12:56PM  
Sep-06-19 03:46PM  
Sep-05-19 08:12AM  
Sep-04-19 04:01PM  
06:00AM  
Aug-24-19 01:46PM  
Aug-21-19 06:03PM  
Aug-20-19 07:38AM  
07:33AM  
06:00AM  
Aug-08-19 05:00PM  
04:02PM  
06:38AM  
Aug-01-19 04:02PM  
Jul-25-19 09:54AM  
Jul-15-19 06:00AM  
Jul-01-19 01:10PM  
Jun-12-19 06:30AM  
May-23-19 04:15PM  
May-22-19 07:00AM  
May-16-19 09:14PM  
May-15-19 01:12PM  
May-09-19 04:02PM  
May-02-19 04:05PM  
Apr-30-19 07:00AM  
Apr-26-19 04:26PM  
11:43AM  
Apr-15-19 04:10PM  
Apr-09-19 07:00AM  
Apr-02-19 04:05PM  
Mar-18-19 11:41AM  
Mar-13-19 04:05PM  
Mar-12-19 07:00AM  
Mar-06-19 07:00AM  
Mar-05-19 04:05PM  
Feb-28-19 05:00PM  
Feb-20-19 04:02PM  
Feb-12-19 07:00AM  
Jan-16-19 02:01PM  
Jan-03-19 08:00AM  
Dec-12-18 07:00AM  
Nov-23-18 08:50AM  
Nov-20-18 04:05PM  
Nov-13-18 04:05PM  
Nov-12-18 04:23PM  
Nov-07-18 04:20PM  
Nov-06-18 08:01AM  
Nov-05-18 10:30AM  
Nov-01-18 04:05PM  
Oct-02-18 07:00AM  
Sep-25-18 04:05PM  
07:30AM  
Sep-05-18 03:20PM  
Sep-04-18 02:30AM  
Aug-29-18 04:05PM  
Aug-16-18 06:29AM  
Aug-13-18 11:16AM  
Aug-08-18 04:02PM  
Aug-07-18 04:02PM  
Jun-25-18 07:10AM  
07:00AM  
Jun-11-18 04:02PM  
Jun-05-18 09:00AM  
Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat immuno-oncology solid tumors. It has collaboration agreements with AbbVie S.a.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; and Ginkgo Bioworks to enable the discovery of new living medicines. The company also has a clinical collaboration with Hoffman-La Roche Ltd. to evaluate SYNB1891 in combination with PD-L1 checkpoint inhibitor in patients with advanced solid tumors. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shea Richard PDirectorDec 13Buy2.747,50020,5507,500Dec 16 05:25 PM